Compliance & Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.
IMPORTANT: This compound is currently on the World Anti-Doping Agency (WADA) prohibited list. Competitive athletes face sanctions for use including in retirement testing programs. Verify current WADA status with your sport's governing body before any research involvement.
Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. The compounds discussed are research chemicals that are not FDA-approved for human use. Always consult a licensed healthcare professional before considering any peptide protocol. WolveStack has no medical staff and does not diagnose, treat, or prescribe. See our full disclaimer.
IGF-1 LR3 injections use a 25-30 gauge insulin syringe for subcutaneous administration into fatty tissue areas like the abdomen, hip, or thigh. Inject slowly over 5-10 seconds at a 45-90 degree angle, rotating injection sites daily to prevent lipodystrophy. Store the reconstituted peptide at 2-8°C and use within 3 weeks to maintain potency. Intramuscular injection may be used for localized muscle site effects but carries higher risk of complications.
What Is Proper IGF-1 LR3 Injection Technique?
Mastering correct injection technique is critical for safety and efficacy. IGF-1 LR3 is administered via subcutaneous (SubQ) injection, meaning the needle penetrates the skin and deposits the peptide into the layer of fatty tissue beneath. This method minimizes systemic side effects compared to intramuscular injection and allows for precise control of dosing.
Proper technique involves using a 25-30 gauge insulin syringe with a half-inch needle length. The angle of injection should be 45-90 degrees relative to the skin surface. A steeper angle (closer to 90 degrees) is preferred for most individuals with adequate subcutaneous fat. Pinch the injection site lightly to stabilize the tissue, then insert the needle smoothly in one motion. Aspirate slightly by pulling back on the plunger to check you haven't hit a blood vessel—if blood appears, withdraw and try a different site. Inject the peptide slowly over 5-10 seconds, then withdraw the needle and apply gentle pressure with a sterile gauze pad.
What Injection Sites Should I Use?
Optimal injection sites include areas with adequate subcutaneous fat and good absorption characteristics: the abdomen (lateral to the navel, 2-3 inches away), upper outer hip/love handle area, and upper thigh (medial or lateral aspects). Never inject into scar tissue, bruised areas, or directly over muscle bellies unless performing intramuscular injections specifically for localized anabolic effects.
Site rotation is essential to prevent lipodystrophy (fatty tissue degradation or nodule formation). Many users follow a systematic rotation: abdomen Monday/Thursday, left hip Tuesday/Friday, right hip Wednesday/Saturday, taking Sunday off. This ensures no single site receives more than two injections per week and allows tissue recovery between uses.
What Needle Gauge and Length Should I Use?
A 25-30 gauge needle is the community standard for IGF-1 LR3 injection. The 25 gauge is thicker and faster to push but may cause slightly more tissue trauma; the 30 gauge is thinner and less traumatic but requires more pressure. Most users prefer 27-29 gauge as a compromise. Needle length should be 0.5 inches (8mm) for reliable subcutaneous penetration in most individuals. Users with minimal subcutaneous fat may use a 25-gauge, 5/16-inch needle.
Insulin syringes come in 30 IU, 50 IU, or 100 IU sizes. For IGF-1 LR3, 100 IU syringes are recommended because dosages (20-100 mcg) require small volumes. If you reconstitute with 10mL of bacteriostatic water, 1 mL of solution contains 10 mcg, making math simple. Use a tuberculin syringe (1mL) for more precise measurement if doses are below 20 mcg.
How Do I Prepare the Injection Site?
Preparation is straightforward but non-negotiable for sterility. Wash your hands thoroughly with soap and warm water for at least 20 seconds. Wipe the injection site with an alcohol prep pad using firm circular motions outward from the center, covering an area about 2 inches in diameter. Allow the alcohol to air dry completely (at least 30 seconds)—injecting into wet alcohol increases discomfort and can reduce effectiveness of the disinfectant.
Keep all supplies sterile: use new syringes, new needles, and new alcohol pads from sealed packets for every injection. Never reuse needles or syringes. If you must use a single syringe for multiple injections (not recommended), change the needle between uses and re-sterilize the injection site.
Should I Use Intramuscular or Subcutaneous Injection?
Subcutaneous injection is the default choice for general systemic effects. It provides excellent absorption, consistent results, and lower complication rates than intramuscular injection. However, some advanced users employ intramuscular (IM) injection to one specific muscle group (e.g., pectorals, shoulders, quads) for localized hypertrophy in that area. IGF-1 LR3 has local paracrine effects when injected directly into muscle, potentially increasing growth in that region.
If attempting IM injection, use a 25-gauge, 1-inch needle at 90 degrees perpendicular to the skin. Aspirate carefully to ensure you haven't entered a blood vessel. The increased needle length and muscle penetration carry higher risk of nerve or blood vessel damage, hematoma formation, and infection. IM injections should only be attempted after extensive practice with SubQ technique and preferably with experienced supervision.
What Happens If I Hit a Blood Vessel?
If you aspirate and blood appears in the syringe barrel, immediately withdraw the needle and move to a different site. Hitting a small blood vessel is rarely an emergency but can result in a bruise or hematoma at the injection site. Never inject into a site where blood is visible. Small hematomas typically resolve within 7-14 days without intervention; apply ice for 10 minutes immediately after to minimize bleeding.
Signs that you may have hit a larger vessel include significant bleeding after needle withdrawal, rapid swelling, or severe bruising developing over minutes. If these occur, apply firm pressure with a clean cloth for 5-10 minutes. If bleeding doesn't stop after 10 minutes or you develop increasing swelling/pain, seek medical evaluation.
What Injection Site Complications Can Occur?
Common injection site issues include lipodystrophy (loss of fat or nodules forming), infection, allergic reactions to the peptide or injection components, and nerve damage (rare but serious). Lipodystrophy is preventable through aggressive site rotation. Infection risk is minimized by strict sterile technique—use fresh sterile supplies for every injection and never reuse needles or syringes. Allergic reactions to IGF-1 LR3 itself are uncommon but may present as localized redness, swelling, or systemic symptoms if bacteriostatic water is contaminated.
Nerve damage typically occurs from injecting too close to major nerve bundles. The abdomen is extremely low-risk; the hip/thigh area carries slightly higher risk if injections are too deep or directed toward the spine/sciatic nerve. Stay at least 3 inches away from bony landmarks and keep injections in the superficial fascia (fatty layer) rather than penetrating deep muscle.
How Do I Store Pre-Filled Syringes?
If you prepare multiple syringes in advance, store them refrigerated at 2-8°C in sealed, sterile conditions. Pre-filled syringes maintain stability for 3-7 days when stored this way. Before injecting, allow the syringe to reach room temperature (5 minutes) to reduce injection discomfort. Never use a pre-filled syringe if the solution is discolored, cloudy, or shows signs of contamination. If any crystallization is visible on the needle hub, discard it and prepare a fresh injection.
What Post-Injection Care Is Recommended?
After injection, apply light pressure with a sterile gauze pad for 10-30 seconds to prevent bleeding and minimize bruising. Avoid massaging the injection site for several hours as this may accelerate peptide dispersal and reduce local effects. Some users report that gentle massage actually distributes the peptide more systemically, while others prefer localized effects and avoid massage entirely. A small bandage can be applied if desired, though most SubQ injections don't require covering.
Minor soreness at the injection site is normal and typically resolves within 24 hours. If you develop pain, swelling, redness, or warmth lasting more than 48 hours, this may indicate infection or a localized reaction—monitor closely and seek medical attention if symptoms worsen.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).
Particle Peptides
Independently HPLC-tested, transparent COAs, comprehensive product range.
Browse Particle Peptides →Limitless Life Nootropics
Premium research peptides with strong customer support and verified purity.
Browse Limitless Life →FAQ: IGF-1 LR3 Injection Technique
Can I inject IGF-1 LR3 into the same site daily?
No. Injecting the same site more than twice per week causes lipodystrophy and reduces absorption. Rotate through at least 4-6 different sites to allow tissue recovery.
How much does injecting wrong technique affect results?
Extremely. Poor technique can cause reduced absorption (hitting muscle or too-deep injection), infection, hematomas, nerve damage, and inability to track results. Master the basics before beginning your cycle.
Should I use a 1mL insulin syringe or a tuberculin syringe?
For most dosages (20-100 mcg), a 100 IU insulin syringe is ideal because it's calibrated for small volumes. If doses are very small (<20 mcg), a tuberculin syringe may be more accurate.
What if I can't see blood when I aspirate—is it safe to inject?
Yes. Aspiration shows obvious vein entry but doesn't guarantee you've avoided all blood vessels. Always inject slowly and watch for unusual swelling. The risk of hitting a vessel is low if you inject into subcutaneous fat rather than deep tissue.
Can I use the same needle to draw from the vial and inject?
Technically yes, but best practice is to use one needle to draw from the vial and a fresh needle for injection. This preserves needle sharpness and reduces skin trauma at the injection site.
Is it OK to inject when the solution is cold from refrigeration?
Injecting cold solution increases discomfort and may slow absorption slightly. Warm the syringe to room temperature for 5 minutes before injection for optimal comfort and consistent results.